Answers are grounded in this paper and cite their sources.
Obesity has emerged as a major global public health challenge. Current pharmacological interventions are limited by suboptimal efficacy and frequent adverse effects, highlighting an urgent demand for innovative therapeutic strategies. Leveraging the well-established probiotic traits of Clostridium butyricum (Cb) and the proven weight-regulating efficacy of glucagon-like peptide-1 (GLP-1), we constructed an engineered C. butyricum strain capable of stable and high-efficiency GLP-1 expression. In this study, we investigated the anti-obesity effects and potential mechanisms of engineered C. butyricum-pMTL007-GLP-1 (Cb-GLP-1), as well as its capacity to ameliorate side effects. Our results demonstrate that Cb-GLP-1 markedly reduces body weight in high-fat diet (HFD)-induced obese mice. Mechanistically, Cb-GLP-1 upregulates the expression of GLP-1R mRNA and pro-opiomelanocortin (POMC) protein within the arcuate nucleus (ARC) of the hypothalamus to suppress appetite and reduce body weight. Meanwhile, Cb-GLP-1 coordinates lipolysis and lipid storage in white adipose tissue by activating protein kinase A (PKA) signaling, upregulating hormone-sensitive lipase (HSL) expression, and downregulating fatty acid-binding protein 4 (FABP4) expression, partially contributing to the amelioration of obesity. Furthermore, Cb-GLP-1 mitigates GLP-1-induced aversive responses by suppressing activation of central nausea center within the brain area postrema (AP), lowering neurotransmitter 5-hydroxytryptamine (5-HT) levels, and downregulating 5-HT 3 receptor (5-HT3R) expression. Moreover, Cb-GLP-1 alleviates hepatic injury and glycolipid metabolic disorders, restores HFD-induced gut microbiota dysbiosis by enriching beneficial genera including Oscillospira and Ruminococcus, reduces pro-inflammatory cytokine production, and reinforces intestinal-barrier function. Collectively, Cb-GLP-1 shows efficacy in weight loss and improved gastrointestinal tolerability, providing a promising microbial therapeutic strategy for obesity treatment. Key points A novel engineered strain Cb-GLP-1 persistently expressing GLP-1 alleviates obesity in HFD-fed mice.Cb-GLP-1 reduces body weight by suppressing appetite and modulating lipolysis and lipid storage in white adipose tissue.Cb-GLP-1 alleviates nausea-like gastrointestinal adverse responses.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: